Unicycive director Gaurav Aggarwal resigns
Unicycive Therapeutics, Inc. reported that director Gaurav Aggarwal resigned from its Board of Directors effective April 6, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Unicycive Therapeutics, Inc. reported that director Gaurav Aggarwal resigned from its Board of Directors effective April 6, 2026.
The company stated that his resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices and expressed gratitude for his service.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation date: April 6, 2026
1 metrics
Resignation date
April 6, 2026
Effective date of Gaurav Aggarwal’s board resignation
Key Terms
Form 8-K, Board of Directors, Emerging growth company
3 terms
Form 8-K regulatory
"FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Board of Directors financial
"resigned from the Board of Directors of the Company"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Unicycive Therapeutics (UNCY) disclose on April 6, 2026?
Unicycive Therapeutics disclosed that director Gaurav Aggarwal resigned from its Board of Directors on April 6, 2026. The company noted there was no disagreement related to its operations, policies, or practices and publicly thanked him for his board service.
Did Gaurav Aggarwal resign from Unicycive Therapeutics (UNCY) over a disagreement?
No, Unicycive stated that Dr. Gaurav Aggarwal’s resignation from its Board of Directors was not due to any disagreement. The company specifically mentioned there were no issues regarding operations, policies, practices, or management decisions that led to his departure.
What reason did Unicycive Therapeutics (UNCY) give for director Gaurav Aggarwal’s resignation?
Unicycive Therapeutics did not attribute Dr. Aggarwal’s resignation to any dispute, instead clarifying it was not driven by disagreements. The filing emphasized there were no conflicts over the company’s operations, policies, or practices and included a note of appreciation for his service.
How did Unicycive Therapeutics (UNCY) characterize its relationship with resigning director Gaurav Aggarwal?
Unicycive characterized the relationship positively, explaining that Dr. Aggarwal’s resignation was not related to any disagreements. The company thanked him for serving on the Board of Directors, suggesting a cooperative departure without cited conflicts or governance disputes.
Who signed the Unicycive Therapeutics (UNCY) Form 8-K announcing the director resignation?
Chief Executive Officer Shalabh Gupta signed the Form 8-K on behalf of Unicycive Therapeutics. His signature indicates the company’s official confirmation of Dr. Gaurav Aggarwal’s resignation from the Board and the accompanying statement that no disagreements prompted the decision.
AI-generated analysis. How Rhea-AI works. Not financial advice.
